

## QIBA Communications Committee (QCC)

28 October 2022 at 11 AM CT

Call Summary

### In attendance

Anne M. Smith, PhD (Co-Chair)

Majid Chalian, MD (Co-Chair)

Maria Athellogou, PhD

Dawn Matthews, MS, MBA

### RSNA

Joe Koudelik

Julie Lisiecki

**Moderator:** Dr. Smith

### The following topics were discussed:

- Review of QIBA kiosk posters for RSNA 2022
- NVIDIA cloud software solutions to aid scientific research
- Suggestions for how best to engage CROs through pharma outreach

### Updates:

#### Poster edits suggested:

- Suggested wording change: "If quantitation is important, some accreditation procedures are not sufficient to meet QIBA Profile claim conformance that is accurate and reproducible."
- Adjustment to the SA mark logo (slightly distorted)
- A different color for greater contrast between the maroon and red colors for the QIBA Profile Tracker graphic

#### NVIDIA solutions - Dr. Athellogou

- Dr. Athellogou gave an overview of NVIDIA's cloud-based solutions for healthcare
- NVIDIA is involved with research in the areas of genomics, radiology, robotics, and other areas
- NVIDIA provides free support to scientific research groups
- Topics discussed include MRI applications for segmentation, hardware and software transfer, and possible applications to QIBA data
- Additional follow up and guidance will be needed from Dr. Chung

#### Clinical Trials Outreach Ideas - Ms. Matthews

- Personal outreach will work the best with known contacts
- Biomarkers that could be used in clinical trials will capture the attention of CROs that manage Pharma trials
- "Hot topics," such as a new tracer or imaging biomarker needed to engage Pharma interest
- Marketing to both Pharma and CROs suggested as a starting point
  - Pharma decisions are made based on cost and what is most relevant to the business
- QIBA papers can be influential if they demonstrate improved performance and reproducibility, e.g., PET Amyloid manuscript, and how to use the Hoffman phantom
- Recommended QIBA contacts include current PET Tau members, Drs. David Scott (Clario), Greg Klein (Roche), and John Seibyl (Invicro)
- Other suggested pharma companies centered around brain research to contact:
  - MedPace
  - ImagePace
  - IXICO
  - CALYX / PAREXEL
  - Takeda Pharmaceuticals (Dr. Schmid)
  - ICON
- Suggestions were centered around brain research, though oncology would be another clinical trial area.

**Ongoing action items (please strike if complete)**

- [Dr. Pepin's](#) MRE promotion work to be shared as an example for other committees re: educational campaign
- [Dr. Pepin](#) to invite imaging CRO contacts re: their perspective and how they use QIBA Profiles in clinical trials
- [Dr. Chung](#) to work on making the connection between AI and QI and how QIBA fits into this picture
- [RSNA staff](#) to invite Drs. Cole and Pepin to next call to provide advice regarding clinical trials
- [RSNA staff](#) to invite Dr. Tom Grist again to the next call (if co-chairs agree)
- [Dr. Smith](#) to reach out to Dr. Schmid (Takeda Pharmaceuticals) and Dr. Seibyl (Invicro)

**Next call:** Thursday, December 8<sup>th</sup> at 11 am CT

**Reference:** About QIBA page: [http://qibawiki.rsna.org/index.php/About\\_QIBA](http://qibawiki.rsna.org/index.php/About_QIBA)

*This new committee intends to help promote QIBA and the value of quantitative imaging to clinical trials and clinical practice and the broader radiology community*